Antiretrovirals Flashcards Preview

Pharmacology > Antiretrovirals > Flashcards

Flashcards in Antiretrovirals Deck (27)
Loading flashcards...
1
Q

Maraviroc

A

CCR5 inhibitor

2
Q

Enfuvirtide

A

Fusion (gp41) inhibitor

Injection site irritation

3
Q

Raltegravir

A

Integrase Strand Inhibitor

Metabolized by Glucuronidation
Very few side effects, well-tolerated

4
Q

NRTI’s

A

Nucleoside Analogs - Chain Terminators
All metabolized by kidney except Abacavir

M184V mutation - will be selected for if you use this as mono therapy. Don’t.

5
Q

Abacavir (ABC)

A

NRTIs
HLA-B57:01 - Steven’s Johnson Syndrome

Should I re-challenge? NO.
I have no idea why. But NO.

Metabolized by LIVER

6
Q

Didanosine

A

NRTIs

Pancreatitis, Peripheral neuropathy

7
Q

Stavudine

A

NRTIs - Thymidine Analog

Pancreatitis, Peripheral neuropathy

8
Q

Lamivudine

A

NRTIs

No SE listed

9
Q

Tenofovir

A

NRTIs

AKI (Fanconi), Bone Density loss

10
Q

Zidovudine (AZT)

A

NRTIs - Thymidine Analog

Bone marrow suppression, Mitochondrial Toxicity

M184V mutation - will be selected for if you use this as mono therapy. Don’t.

11
Q

Zalcitabine

A

NRTIs

Aphthous Ulcerations

12
Q

Delaviridine

A

NNRTI - bind to a pocket in RT’s
Liver metabolism

K103N mutation

13
Q

Efavirenz

A

NNRTI- bind to a pocket in RT’s
Liver metabolism

K103N mutation

14
Q

Etravirine

A

NNRTI- bind to a pocket in RT’s
Liver metabolism

K103N mutation

15
Q

Elvitegravir

A

Integrase Strand Inhibitor

Metabolized by Glucuronidation
Very few side effects, well-tolerated

16
Q

Dolutegravir

A

Integrase Strand Inhibitor

Metabolized by Glucuronidation
Very few side effects, well-tolerated

17
Q

Protease Inhibitors

A

Metabolized by liver, inhibit isoenzyme 3A4
End in -navir

GI side effects

I84V mutation

18
Q

Atazanavir

A

Protease inhibitor

I84V mutation

19
Q

Darunavir

A

Protease inhibitor

I84V mutation

20
Q

Indinavir

A

Protease inhibitor

I84V mutation

21
Q

Cobicistat

A

CYP450 inhibitor
Like Ritonavir
Often combined with Elvitegravier

22
Q

When to start therapy?

A

NOW. As soon as someone has a diagnosis. NEVER STOP THERAPY.

23
Q

Post Exposure Prophylaxis

A

Within 72 hours for 28 days

Reduces risk by 80%

24
Q

M184V

A

NRTI mutation

25
Q

K103N

A

NNRTI mutation

26
Q

Ritonavir

A

Inhibits CYP450, boosting the action of protease inhibitors

27
Q

Preferred Therapy Regimens

A

R/PI + 2 NRTI’s

INSTI + 2 NRTI’s